Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05117541
Other study ID # 21F.415
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date August 2, 2021
Est. completion date March 30, 2026

Study information

Verified date November 2023
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study explores how psychosocial factors (e.g., chronic stress, depression) may lead to liver disease progression such as liver cirrhosis or liver cancer among Korean American chronic hepatitis B infection patients. Gathering health information over time from Korean Americans with chronic hepatitis B infection may help doctors find better methods of treatment and on-going care.


Description:

PRIMARY OBJECTIVES: I. To estimate the prevalence of chronic hepatitis B (CHB) phenotype and liver disease severity at enrollment visit, and model how multiple social-environmental, psychosocial, behavioral, clinical and biological attributes are associated with variation in CHB phenotype and disease severity. II. To identify how these same attributes are associated with disease progression over time. SECONDARY OBJECTIVE: I. To examine the moderating effects of these multi-level factors on the relationship between liver disease progression and adverse liver disease outcome (e.g., hepatocellular carcinoma [HCC]), as well as mediating effects of liver disease progression on the relationship between psychosocial factors and liver cancer or death. EXPLORATORY OBJECTIVE: I. Using an explanatory mixed methods approach, to understand the care-seeking behaviors, and dynamics of care, within an ethnically concordant liver disease care model, and how these factors may have both direct and mediational effects on adherence, treatment effectiveness, and adverse disease outcomes. OUTLINE: Patients participate in interviews over 20-40 minutes and undergo collection of hair samples at baseline and 18-24 months. Patients' medical records are also reviewed.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 365
Est. completion date March 30, 2026
Est. primary completion date March 30, 2026
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Provide signed and dated informed consent form - Willing to comply with all study procedures and be available for the duration of the study - Korean-American male or female, age over 18 and older - CHB Patients who have lab and medical record data (including hepatitis B virus [HBV] deoxyribonucleic acid [DNA] viral load, hepatitis B virus e Antigen [HBeAg] status, and liver enzyme values) exist from 2015 or before Exclusion Criteria: - Patients who have received a diagnosis of HCC, although they may have been diagnosed with cirrhosis - Patients who have been diagnosed with other viral infections (hepatitis C virus [HCV], human immunodeficiency virus [HIV], etc.) - Patients who have total baldness

Study Design


Intervention

Other:
Interview
Participate in interviews
Procedure:
Biospecimen Collection
Undergo collection of hair samples
Other:
Electronic Health Record Review
Medical records are reviewed

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change Chronic hepatitis B (CHB) phenotype Categorized as follows: 1) immune tolerant, 2) immune active with hepatitis B virus e antigen (HBeAg)(+), 3) immune active with HBeAg(-), and 4) inactive carrier, with patients not fitting into one of these four phenotypes classified as 5) indeterminant. Phenotype at study enrollment will be calculated At start of treatment
Primary Change Liver disease severity Will be estimated using fibrosis 4 (FIB-4) (a parameter calculated using alanine aminotransferase [ALT] and aspartate aminotransferase [AST] values, platelet count and age) and APRI (AST to platelet ratios). At end of treatment
Secondary Change in hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels Baseline to 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT04704024 - Reducing Vertical Transmission of Hepatitis B in Africa Phase 3
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00371150 - Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Phase 4
Active, not recruiting NCT03519113 - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 Phase 2/Phase 3
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Completed NCT01488526 - Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed NCT00489099 - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) Phase 3
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Recruiting NCT03865966 - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Phase 2/Phase 3
Completed NCT02443233 - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong N/A
Completed NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users Phase 3
Active, not recruiting NCT03887702 - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Phase 3
Completed NCT02304315 - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients Phase 2